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Anti-latent TGF-b binding protein-1 antibody or synthetic oligopep-
tides inhibit extracellular matrix expression induced by stretch in cul-
tured rat mesangial cells. Transforming growth factor-b (TGF-b) is
usually secreted as a large latent complex associated with latent TGF-b
binding protein-1 (LTBP-1), which is known to bind to extracellular matrix
(ECM) components. Although the LTBP-ECM interaction has been
suggested to play a role in the activation and biological action of TGF-b,
the precise mechanism is still unclear. In glomerular hypertension mes-
angial cells are believed to perceive the increased cyclic strain and we have
recently reported that cyclic mechanical stretch in vitro enhances the
expression of ECM components via an autocrine/paracrine secretion of
TGF-b in cultured rat mesangial cells. Therefore, in this study we
examined the role of LTBP-1 in the stretch-induced, TGF-b-mediated
ECM expression. Mesangial cells expressed mRNA for short and long
forms of LTBP-1 (LTBP-1S and LTBP-1L, respectively). Mesangial cells
were subjected to cyclic stretch to provide a maximal elongation of 20% at
a rate of 60 cycles/min for 24 to 36 hours in the presence of polyclonal
antibody raised against human LTBP-1 or synthetic oligopeptides corre-
sponding to the N-terminal portions of human LTBP-1, which may work
as competitive inhibitors against the LTBP-ECM association. Both anti-
LTBP-1 antibody (Ab39) and synthetic oligopeptides inhibited the stretch-
induced mRNA expression of type I collagen and fibronectin in a
dose-dependent manner, but the inhibition by Ab39 or the oligopeptides
was recovered by adding recombinant TGF-b. Ab39 or the oligopeptides
did not change the effect of exogenously added TGF-b, such as growth-
inhibition in mink lung epithelial cells. These results suggest that mesan-
gial cells secrete TGF-b as a large latent complex, and the LTBP-ECM
interaction may be a pivotal step in TGF-b action and ECM accumulation,
providing a new therapeutic strategy against progression of glomeruloscle-
rosis and other fibrotic diseases.
Transforming growth factor-b (TGF-b) is a 25 kDa-dimer that
has been shown to be a multifunctional regulator of cell prolifer-
ation and differentiation [1] and to contribute to the accumulation
of extracellular matrix (ECM) proteins. TGF-b plays an impor-
tant role in many physiological conditions such as fetal develop-
ment, wound healing and immunological stability but also in some
pathological states. It is suggested that overproduction of TGF-b
may be related to the pathogenesis of a number of fibrotic
diseases including lung fibrosis, liver cirrhosis, keroid formation as
well as glomerulonephritis and glomerular sclerosis [2]. For the
last several years, efforts have been made to prevent the progres-
sion of these diseases by blocking TGF-b’s action by utilizing
neutralizing antibodies [3] or decorin [4] in anti-Thy-1 glomeru-
lonephritis rat or other animal models. However, it is still difficult
to apply them to the chronic diseases or human diseases and new
therapeutic approaches should be developed to regulate TGF-b
activity.
TGF-b is usually secreted in a biologically inactive form as
small or large latent complex. Large latent TGF-b complex
(LLTC) is composed of three distinct components, that is, mature
TGF-b, latency-associated peptide (LAP) and latent TGF-b
binding protein-1 (LTBP-1). Both TGF-b and LAP are disulfide-
linked homodimers. LAP is the N-terminal portion of the TGF-b
precursor and is non-covalently bound to mature TGF-b to form
the small latent TGF-b complex. Small latent TGF-b complex can
be detected in some transformed cell lines. On the other hand,
LTBP-1 is a single molecule that is bound to LAP by a disulfide
bond, forming LLTC, which is seen in many cell types [5, 6].
Indeed, LTBP-1 is reported to be expressed in various cells such
as human platelets [7, 8], fibroblasts [5, 9], fibrosarcoma cells [9,
10], smooth muscle cells [11], glioblastoma cells [12], osteosar-
coma cells [13], human erythroleukemia cells [14] and, moreover,
some cells derived from epithelial and endothelial cells [10]. So
far three isoforms (LTBP-1, -2 and -3) have been identified
[15–17], and LTBP-1 is known to have at least two alternative
spliced forms, the long one (LTBP-1L) and short one (LTBP-1S),
depending on the length of the N-terminal portion. Studies on the
structure of the latent TGF-b complexes and the mechanism of
activation may give information that will allow the regulation of
TGF-b activity.
LTBP-1 contains 17 or 18 epidermal growth factor (EGF)-like
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repeats and four copies of 8-cysteine repeats. EGF-like repeats
are thought to be important in the protein-protein interaction
[18], but the role of 8-cysteine repeats is unknown. LTBP-1 has
been shown to bind covalently to ECM on its N-terminal domain,
resulting in the storage of LLTC in the ECM [9, 19–22]. LTBP-1L
appears to bind more efficiently to ECM than LTBP-1S [19].
ECM-bound LLTC is released by proteases such as plasmin that
cleave the binding between ECM and LTBP-1 at a specific site.
Released LLTC is activated at the cell surface to release mature
TGF-b. Recent data indicate that the LLTC-ECM interaction via
LTBP-1 is the first step in the sequence of activation process for
TGF-b [21–23]. Moreover, recent studies show that LTBP-1 exists
as an extracellular fibrillar structure and plays a role in the storage
of TGF-b as LLTC [24, 25].
Increased glomerular hydraulic pressure is generally observed
in chronic renal diseases and has been suggested as the major
responsible factor underlying the progression of glomerular scle-
rosis [26–29], although the mechanism by which glomerular
Fig. 1. Structures of latent transforming
growth factor-b binding protein-1 (LTBP-1)
and synthetic oligopeptides. (A) LTBP-1L (long
form) and LTBP-1S (short form) are two
alternative spliced forms of LTBP-1 and differ
only by the length of the N-terminal region.
The N-terminal end of LTBP-1 interacts with
extracellular matrix (ECM). The location of the
amino acids where the synthetic oligopeptides
(peptides 1 to 4) were based on are indicated.
(B) Amino acid sequences of peptides 1 to 4.
Symbols are: (u) epidermal growth factor
(EGF)-like repeat; (f) eight cysteine repeats.
Fig. 2. Effect of stretch on mRNA expression
of extracellular matrix (ECM) components and
transforming growth factor-b1 (TGF-b1). After
mesangial cells were exposed to cyclic stretch at
a maximal elongation of 20% for 36 hours, the
mRNA expression of fibronectin, type I
collagen (collagen I) and TGF-b1 of mesangial
cells in the absence or the presence of anti-
TGF-b neutralizing antibodies (20 mg/ml) or
non-immune rabbit IgG (20 mg/ml) was
analyzed by Northern blot.
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hypertension leads to the accumulation of ECM components is
still unknown. Intraglomerular pressure is transmitted to the
capillary walls by Laplace’s law and results in mechanical stretch
to glomerular mesangial cells [30, 31]. It has been shown that
mesangial cells in culture, when they are exposed to mechanical
stretch, exhibit alterations in cell morphology, proliferation and
activation of S6 kinase and expression of protooncogenes or
cyclooxygenase [31–33]. Moreover, it is demonstrated that mes-
angial cells undergoing cyclic stretching increase the synthesis of
types I and IV collagen, laminin and fibronectin, major compo-
nents of ECM [31]. Recently, we have found that the stretch-
induced expression of ECM components is mainly mediated by an
autocrine/paracrine secretion of TGF-b, suggesting that capillary
expansion and stretching of mesangial cells by glomerular hyper-
tension might provoke ECM production via TGF-b [34–36].
This study was designed, therefore, to determine the role of
LTBP and the LTBP-ECM interaction in the stretch-induced
ECM expression that is mediated by TGF-b in cultured mesangial
cells. Because it is not known whether mesangial cells express
LTBP, we first investigated the mRNA expression of LTBP-1 in
mesangial cells and then examined whether specific anti-LTBP-1
antibody or synthetic oligopeptides, which are expected to block
the LTBP-ECM interaction, may alter the TGF-b-mediated ECM
expression by the stretch. The results show that mesangial cells
express mRNA for both LTBP-1S and LTBP-1L, and that anti-
LTBP-1 antibody and synthetic oligopeptides inhibited the
stretch-induced mRNA expression of type I collagen in a dose-
dependent manner. These results suggest that mesangial cells
secrete TGF-b as large latent complex and the LTBP-ECM
interaction may be a pivotal step in TGF-b action and ECM
accumulation. The results also provide a new therapeutic strategy
for prevention of progression of glomerulosclerosis.
METHODS
Cell culture
Mesangial cells were obtained by culturing glomeruli isolated
from kidneys of 200 to 250 g male Wistar rats by a conventional
sieving method [37, 38]. The cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 20% fetal
calf serum (JRH Biosciences, Lenexa, KS, USA), 2 mM L-
glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin
(Wako Pure Chemical Industries, Osaka, Japan). The glucose
concentration of the media was 5.55 mM (100 mg/dl). Before each
experiment, cells were serum-deprived by incubating in DMEM
containing 0.2% bovine serum albumin (Fraction V; Sigma Chem-
ical Co. St. Louis, MO, USA) for 24 hours. The cells between 5
and 12 passages that had just become confluent were used in this
study.
Application of mechanical stretch to cultured cells
Mesangial cells were subjected to mechanical cyclic stretch
using Flexercell Strain Unit FX-2000 (Flexercell Corp., Mckees-
port, PA, USA). The cells were seeded on six-well plates (25 mm
diameter) of a flexible silicone-rubber or rigid bottom coated with
type I collagen (Flex I or Flex II culture plate, respectively;
Flexercell Corp.). A microprocessor controls negative pressure to
the flexible bottoms resulting in reproducible deformation of the
silicone rubber and the attached cells, providing a maximal
elongation of 20%. All experiments were carried out using
alternating cycles of 0.5 s stretch and 0.5 s relaxation at a rate of
60 cycles/min at 37°C with 95% air and 5% CO2 in a humidified
incubator.
Northern blot analysis
After cultures with and without mechanical stretch, the cells
were washed once with ice-cold Dulbecco’s phosphate-buffered
Fig. 3. LTBP-1 mRNA expression in mesangial cells. (A) Northern
hybridization to poly(A1) RNA from mesangial cells were performed
using the EcoRI restriction fragments of LTBP-1S cDNA to detect mRNA
for both LTBP-1L and LTBP-1S (i) and the EcoRI/SacII fragments that
are specific to LTBP-1L (ii) as probes. (B) Time course of the effect of
mechanical stretch on mRNA expression of LTBP-1L and LTBP-1S. (C)
Densitometric quantitation of the blots. Symbols are: (f) LTBP-1S; (o)
LTBP-1L. The data are expressed as mean 6 SD of the relative ratio of
LTBP-1L (or LTBP-1S)/GAPDH mRNA from three separate experi-
ments.
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saline (PBS), and then solution D (4 M guanidinium thiocyanate,
25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, 0.1 M 2-mercapto-
ethanol) was added. Total RNA was prepared by acid guani-
dinium isothiocyanate phenol chloroform method [39]. Total
RNA (10 mg per each lane) was separated by formaldehyde/1.0%
agarose gel electrophoresis, and transferred onto a nylon mem-
brane (Hybond N, Amersham, Buckinghamshire, UK). About
500-base pair BglI/EcoRI fragments of rat TGF-b1 from plas-
mid clones were prepared for a probe and labeled with [a-32P]
dCTP (Amersham) by random primer method. The specific
activity of the probe was 5 to 9 3 108 cpm/mg cDNA.
Hybridization was performed at 42°C in 0.87 M NaCl, 50%
formamide, 0.5% SDS and 167 mg/ml salmon sperm DNA. The
membrane was washed in 0.1 3 SSC and 0.1% SDS at 55°C and
autoradiographed. The radioactivity of corresponding bands
was measured quantitatively by Fuji BAS 2000 Bio-Image
Analyzer (Fuji Film, Tokyo). After stripping radioactive probes
off the membranes, they were rehybridized with 32P-labeled
cDNA probes of rat type I collagen and fibronectin; glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was used as an inter-
nal control. As probes for LTBP-1S and LTBP-1L, 2.5-kilo-base
(kb) pair EcoRI fragments of human LTBP-1S cDNA and 500-
base pair EcoRI/SacII fragments of LTBP-1L were used, respec-
tively.
Fig. 4. Effect of antibody against LTBP-1
(Ab39) on the stretch-induced mRNA
expression of ECM components and TGF-b1.
(A) The mRNA expression of fibronectin, type
I collagen (Collagen I) and TGF-b1 was
analyzed by Northern blot in mesangial cells
with or without stretch for 36 hours, in the
presence of Ab39 (31000) or control rabbit
serum (31000). The data are representative of
four separate experiments. (B) Densitometric
quantitation of the blots for fibronectin (FN),
type I collagen (Col I) and TGF-b1. The results
were expressed as mean 6 SD (N 5 4) of the
relative ratio corrected by GAPDH mRNA.
*Significantly different, P , 0.05, by Student’s
t-test. NS is not significant.
Hori et al: Inhibition of ECM by anti-LTBP-1 Ab or oligopeptides 1619
Mink lung epithelial cell growth-inhibition assay
The assay was performed to examine the effect of the oligopep-
tides or Ab39 on TGF-b’s growth inhibitory effect in mink lung
cells as described [38]. In brief, mink lung cells were plated into
96-well culture plates in DMEM containing 10% FCS. After
incubation for 24 hours the medium was changed to DMEM
containing 1% FCS. 24 hours later test or control samples were
added and the cells were incubated for another 16 to 24 hours.
Subsequently, 18 kBq/well [3H]-thymidine was pulsed for three to
five hours and the amount of [3H]-thymidine incorporated into
trichloroacetic acid (TCA)-precipitable materials was measured
by a liquid scintillation counter.
Anti-latent TGF-b binding protein antibody and oligopeptides
Rabbit polyclonal antibody Ab39 was raised against purified
LTBP-1 according to the procedures as described [5, 7, 14]. Ab39
has been well characterized and shown to react specifically with
LTBP-1 [12, 24, 25]. Based on the amino acid sequences of human
LTBP-1S and LTBP-1L, four different oligopeptides, peptide 1,
peptide 2, peptide 3 and peptide 4, were synthesized using a
peptide synthesizer (model 431A; Applied Biosystems, Foster
City, CA, USA). Amino acid sequences of them are shown in
Figure 1B.
Other materials
Rat TGF-b1 cDNA was a gift of Dr. T. Nakamura (Osaka
University, Osaka, Japan). Human platelet TGF-b1 and rabbit
anti-TGF-b neutralizing antibody were purchased from R&D
Systems, Inc (Minneapolis, MN, USA). Rat type I collagen cDNA
was provided by Dr. S. Katayama (Saitama Medical School,
Saitama, Japan), and rat fibronectin cDNA was a gift of Dr. R.O.
Hynes (Massachusetts Institute of Technology, Cambridge, MA,
USA). All other chemicals were of the best grade commercially
available.
RESULTS
Synthetic oligopeptides
Figure 1 illustrates the structures of LTBP-1L and LTBP-1S
and the location of the synthesized oligopeptides in the LTBP
molecules. Peptide 1 and peptide 2 are derived from the N-
terminal 20 amino acids, which are common to both LTBP-1S and
LTBP-1L. Peptide 3 and peptide 4 correspond to the N-terminal
end of LTBP-1L, which is spliced out in LTBP-1S.
Effect of mechanical stretch on mRNA expression of ECM
proteins and TGF-b in mesangial cells
Figure 2 shows the effect of cyclic mechanical stretch on mRNA
expression of ECM components and TGF-b1. As we previously
reported, mechanical stretch at a maximal elongation of 20% for
36 hours enhanced mRNA expression of ECM components,
fibronectin and type I collagen, and TGF-b1 in mesangial cells
[34]. Addition of anti-TGF-b neutralizing antibodies (20 mg/ml)
blocked the stretch-induced mRNA expression of fibronectin and
type I collagen, suggesting that induction of the ECM components
may be mediated by TGF-b. In contrast, anti-TGF-b neutralizing
antibodies appeared to exert little effect on TGF-b1 mRNA
expression itself, suggesting that there may be no significant
autoinduction of TGF-b1 by stretch in our conditions.
LTBP-1 mRNA expression in mesangial cells
It is suggested that alternative splicing gives two different
transcripts of rat LTBP-1 mRNA at the size of 6.2 kb and 5.3 kb
encoding LTBP-1L and LTBP-1S, respectively [6, 19]. Northern
blot analysis shows that mesangial cells express mRNA for both
LTBP-1L and LTBP-1S using the EcoRI restriction fragment of
LTBP-1S as a probe (Fig. 3A). In contrast, when we used the
EcoRI/SacII fragment, which corresponded to the N-terminal
region of LTBP-1L as a probe, only one transcript was hybridized
(Fig. 3A), indicating the presence of LTBP-1L mRNA. The
mRNA levels of LTBP-1L and LTBP-1S increased during the first
24 hours after mesangial cells were exposed to mechanical stretch
and then appeared to be decreased at 36 hours (Fig. 3 B, C). The
mRNA levels of LTBP-1S were constantly higher than those of
LTBP-1L.
Fig. 5. Dose-dependency of the effect of Ab39 on mRNA expression of
type I collagen. (A) The mRNA expression of type I collagen in the
presence of various concentrations of Ab39 as indicated. Abbreviations
are: C, control rabbit serum; A, Ab39. The data are representative of four
separate experiments. (B) Densitometric quantitation of the blots. The
results were expressed as mean 6 SD (N 5 4) of the relative ratio of Col
I/GAPDH mRNA. *P , 0.05, by Student’s t-test.
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Effect of antibody against LTBP-1 (Ab39) on mRNA expression
of ECM components
Next we determined if Ab39, a polyclonal rabbit antibody
against human LTBP-1, might have any effect on the stretch-
induced, TGF-b-mediated expression of ECM components. Fig-
ure 4 shows that Ab39 inhibited the stretch-induced mRNA
expression of fibronectin and type I collagen, while control serum
had no effect. TGF-b1 mRNA expression induced by stretch was
not altered by adding Ab39. The inhibitory effect of Ab39 on the
stretch-induced mRNA expression of type I collagen was dose-
dependent (Fig. 5).
Effect of synthetic oligopeptides on mRNA expression of ECM
components
Oligopeptides (peptides 1 to 4) corresponding to the 20 amino
acids at the N-terminal portion of LTBP-1L or LTBP-1S were
synthesized (Fig. 1). The addition of peptides 3 and 4 (10 mg/ml)
to mesangial cell culture significantly inhibited the stretch-in-
duced mRNA expression of fibronectin and type I collagen (Fig.
6). In contrast, addition of peptides 1 and 2 had no significant
inhibition. The synthetic oligopeptides had no effect on TGF-b1
mRNA expression. The inhibitory effects of peptides 3 and 4 were
dose-dependent and inhibition was observed at concentrations
greater than 10 mg/ml (Fig. 7).
Recovery of the inhibitory effect of Ab39 or the synthetic
oligopeptide on mRNA expression of ECM components by
adding recombinant TGF-b
To examine whether Ab39 or synthetic oligopeptides cross-
react with TGF-b signaling receptors or TGF-b itself, the rescue
experiments were performed. Inhibition of stretch-induced type I
collagen mRNA expression by Ab39 or synthetic peptide 4 was
Fig. 6. Effect of synthetic oligopeptides from
LTBP-1 on stretch-induced mRNA expression
of ECM components and TGF-b1. (A) The
mRNA expression of fibronectin, type I
collagen and TGF-b1 was analyzed by Northern
blot in mesangial cells with or without stretch
for 36 hours, in the presence of synthetic
oligopeptides, peptides 1 to 4, (10 mg/ml) or
somatostatin (10 mg/ml) as a control peptide.
The data are representative of four separate
experiments. (B) Densitometric quantitation of
the blots. The results were expressed as
mean 6 SD (N 5 4) of the relative ratio of Col
I/GAPDH mRNA. *P , 0.05, by Student’s t-
test.
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recovered by adding more than 10 pM of recombinant TGF-b to
the culture media (Fig. 8).
Ab39 or the synthetic oligopeptide did not change the effect of
exogenously added TGF-b
Finally, to exclude the possibility that Ab39 or synthetic oli-
gopeptides affected the cellular response to exogenously added
TGF-b, we performed a growth-inhibition assay in mink lung
cells. As shown in Figure 9, Ab39 or peptides 3 and 4 did not alter
the growth-inhibitory effect of 10 or 40 pM TGF-b in these cells,
whereas anti-TGF-b neutralizing antibody almost completely
abolished the inhibitory effect of TGF-b. Moreover, Ab39 or the
oligopeptides had no effect on the induction of type I collagen by
recombinant TGF-b in rat mesangial cells (data not shown).
DISCUSSION
In this study we take advantage of our recent finding that
mechanical stretch induces mRNA expression of ECM compo-
nents via an autocrine/paracrine secretion of TGF-b in cultured
mesangial cells [34] to determine the role of LTBP-1 and the
LTBP-ECM interaction in glomerular mesangial cells. Either
anti-LTBP-1 antibody or synthetic oligopeptides, which may block
the LTBP-ECM interaction, inhibited the stretch-induced mRNA
expression of fibronectin and type I collagen. These results
suggest that the LTBP-ECM interaction may be a pivotal step in
the action of TGF-b and ECM accumulation.
The mRNA expression of LTBP-1 was seen in various normal
rat tissues including kidney, and it is reported that LTBP-1 is
Fig. 7. Dose-dependency of the inhibitory effect of peptides 3 and 4 on mRNA expression of ECM components. The dose-dependency of the effect of
peptide 3 (A) and peptide 4 (C) on mRNA expression of type I collagen. The data are representative of four separate experiments. Abbreviations in
A are: C, control peptide (somatostatin); P, synthetic peptide 3. Abbreviations in C are: C, control peptide (somatostatin); P, synthetic peptide 4. By
densitometric quantitation of the blots for peptide 3 (B) and peptide 4 (D), the results were expressed as mean 6 SD (N 5 4) of the relative ratio of
Col I/GAPDH mRNA compared to control with stretch. *P , 0.05, by Student’s t-test.
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up-regulated in the renal cortex of adriamycin nephrosis rat [40].
However, it is not known whether LTBP-1 is expressed in the
glomerulus or glomerular cells. Our results show that mRNAs for
both LTBP-1L and LTBP-1S are expressed in cultured mesangial
cells. The mRNA levels of LTBP-1S were higher than those of
LTBP-1L. We previously reported that TGF-b is produced by
cultured rat mesangial cells largely in a latent form, and that the
secreted TGF-b regulates cell proliferation in an autocrine/
paracrine manner [34, 38]. Thus, it is likely that mesangial cells
produce TGF-b as large latent complex with LTBP-1, followed by
activation to a mature or active form. Our results also show that
mRNA expression of LTBP-1L and LTBP-1S are stimulated by
mechanical stretch in a time-dependent manner, although the
physiological significance of this phenomenon has not been
determined. It may be that LTBP-1 and TGF-b should be
simultaneously stimulated to form large latent complex on the cell
surfaces or in the ECM before being activated.
Our results show that some synthetic peptides we developed
inhibit the stretch-induced, TGF-b-mediated ECM expression. It
is known that LTBP-1 binds to the ECM through the N-terminal
end of LTBP-1 [9, 19, 22, 23], and thus it may be expected that
peptides 1 through 4 may competitively inhibit the binding of
LTBP-1 and ECM. However, an inhibitory effect on the stretch-
enhanced mRNA expression of ECM components was more
potent with peptides 3 and 4, which were derived from the
N-terminal region of LTBP-1L, than peptides 1 and 2 from that of
LTBP-1S. Indeed, peptides 1 and 2 had little applicable effect on
the stretch-induced mRNA expression of type I collagen and
fibronectin. Thus, LTBP-1L bind more efficiently to ECM than
LTBP-1S [19] and the activation of the latent complex may be
more dependent on LTBP-1L binding to ECM components.
Our results also show that the oligopeptides did not alter the
stretch-induced TGF-b mRNA expression, excluding the possibil-
ity that they inhibit TGF-b synthesis. Other possibilities including
inhibition of TGF-b binding to its receptor, inhibition of TGF-b
signal transduction within the cells and nonspecific inhibition are
all unlikely. First, the peptides did not alter the TGF-b’s growth-
inhibitory effect in mink lung cells (Fig. 9) or profibrotic effect in
mesangial cells (data not shown). Second, the inhibitory effect of
the peptides on the stretch-induced ECM expression was reversed
by adding more than 10 pM of recombinant TGF-b (Fig. 8). It is
suggested, therefore, that the target of an inhibitory effect of the
peptides is probably at the stage of TGF-b activation through
inhibition of the LTBP-ECM association.
Similar to the synthetic oligopeptides, anti-LTBP-1 antibody
Ab39 also exert an inhibitory effect on the stretch-induced ECM
expression probably by blocking the LTBP-ECM interaction.
However, another possibility is that anti-LTBP antibody, by
making large complex with LLTC, may somehow prevent the
activation process that is to be initiated by proteases such as
plasmin without inhibiting the LTBP-ECM association. Thus, the
mechanism by which Ab39 inhibits the stretch-induced, TGF-b-
mediated ECM expression might be somewhat different from that
of synthetic oligopeptides.
The mechanism of activation of latent TGF-b is not well
understood. Before TGF-b is activated by plasmin, throm-
bospondin [41] or other mechanisms to release mature TGF-b,
ECM-bound LLTC has to be released by the proteases from
ECM. Hence, the LLTC-ECM interaction via LTBP-1 may be the
first step in the sequence of activation process for TGF-b [21, 22,
42]. Our present study suggests that activation of latent complex
and the subsequent events may not occur unless LTBP-1 is bound
to ECM, and that the LTBP-ECM interaction is a critical step in
the activation of latent TGF-b.
Overproduction of TGF-b has been shown to be related to the
pathogenesis of a number of fibrotic processes including glomer-
ulonephritis and glomerular sclerosis. For the last several years,
efforts have been made to prevent the progression of these
diseases by blocking TGF-b’s action with neutralizing anti-TGF-b
Fig. 8. Recovery of the inhibitory effect of Ab39 or the synthetic oligopep-
tide on mRNA expression of ECM components by adding recombinant
TGF-b. The mRNA expression of type I collagen with or without stretch
was examined in the presence of (A) Ab39 (1:100 dilution) or (B) peptide
4 (20 mg/ml) with or without adding recombinant TGF-b (10 pM). The
results were expressed as mean 6 SD of the relative ratio of Col I/GAPDH
mRNA by densitometric analysis from four separate experiments. *P ,
0.05, by Student’s t-test. Abbreviations are: R.S., control rabbit serum,
C.P., control peptide (somatostatin).
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antibodies [3], decorin [4] or soluble TGF-b receptors, but it has
been difficult to apply these maneuvers to human diseases.
Irrespective of the mechanism, the present study may be the first
report showing that the oligopeptides can block the TGF-b action
with potential clinical application. Oligopeptides may be better
candidates for the inhibitors of TGF-b, because they are easy to
be synthesized and more stable against enzymatic digestion or
immunological inactivation than high-molecular-weight proteins
such as neutralizing antibodies or decorin.
In conclusion, the present study shows that blockade of the
LTBP-ECM interaction using specific anti-LTBP-1 antibody or
synthetic oligopeptides can inhibit the stretch-enhanced ECM
expression mediated by TGF-b, and suggests that the LTBP-ECM
interaction is a pivotal step in TGF-b activation and ECM
accumulation. The data provide a new therapeutic strategy against
progression of glomerulosclerosis and other fibrotic diseases.
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APPENDIX
Abbreviations used in this article are: DMEM, Dulbecco’s modified
Eagle’s medium; ECM, extracellular matrix; EGF, epidermal growth
factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LAP, laten-
cy-associated peptide; LLTC, large latent TGF-b complex; LTBP-1, latent
TGF-b binding protein-1; LTBP-1L, long form of LTBP-1; LTBP-1S,
short form of LTBP-1; PBS, phosphate buffered saline; TCA, trichloro-
acetic acid; TGF-b, transforming growth factor-b.
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